Menu
Evaluating vast search spaces with small data AI and experimentally derived datasets
The Optim.AI™ platform is disease-agnostic and can be applied across a spectrum of biological models to help provide scientists and healthcare professionals with the ability to efficiently evaluate large combinatorial search spaces without traditional limitations.
Since we do not use high throughput screening or require vast amounts of external data, our technology is versatile and can be used from preclinical drug development through clinical trials, and for clinical decision support.
The core of Optim.AI™ utilizes small data AI to expand the universe of each phenotypic response dataset to solve for every possible combinatory outcome. This is a key benefit as we are not forced to pre-select a limited number of combinations within a drug panel for evaluation
and we eliminate potential holes of knowledge.
Optim.AI™ results include all predicted drug-drug interactions which can represented by a 3D parabolic response map that indicates an optimum
with 2 drugs. Rather than providing a binary YES/NO output, Optim.AI™ ranks all outcomes by an assigned normalized cell viability value so that
relative efficacy and ranges of likely sensitivity and resistance can be gauged.
1 Research Link, #05-45, Singapore 117604.
KYAN Technologies is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory
HCI License Number:
L/23I0025/CLB/001/232
